Multiple myeloma trials in Australia

In Australia 51 Also abroad 703

51 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Fitzroy, Melbourne
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 1Taking people
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Parkville
Age
18 years and over
People
160 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07558915
Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Adelaide, Auchenflower, Camperdown, Fitzroy, Geelong, Heidelberg, Herston, Hobart, Launceston, Nedlands, St Leonards
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 1/2Taking people
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Where
Fitzroy, Randwick
Age
18 years and over
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Where
Adelaide, Camperdown, Melbourne, Prahan, Waratah
Age
18 years and over
People
120 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT05927571 · EU 2023-504657-13-00
Phase 1/2Taking people
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Adelaide, Fitzroy, Liverpool, Melbourne, Randwick, Wollongong
Age
18 years and over
People
150 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07455851 · EU 2025-522776-93-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Adelaide, Benowa, Brisbane, East Melbourne, Heidelberg, Melbourne, Perth, Southport
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Camperdown, Geelong, Liverpool, Nedlands, New South Wales, Wollongong, Woolloongabba
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 2Taking people
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Where
Camperdown, Clayton, Heidelberg, Murdoch, Woolloongabba
Age
18 years to 80 years
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07149857 · EU 2025-521975-30-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Box Hill, Brisbane, Clayton, Fitzroy, Melbourne, Murdoch, Nedlands, Southport
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 2Taking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Bedford Park, Birtinya, Concord, Fitzroy, Wollongong
Age
18 years and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Darlinghurst, South Brisbane
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Birtinya, Box Hill, Liverpool, Melbourne, Nedlands, Waratah, Wollongong
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 1/2Taking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Fitzroy, Melbourne, Nedlands, Wollongong
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Adelaide, Brisbane, Camperdown, Clayton, Liverpool, Melbourne, Murdoch
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Benowa, Camperdown, Fitzroy, Melbourne, Richmond
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Fitzroy, Liverpool, Richmond, Waratah
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 1/2Taking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Clayton, Fitzroy, Garran, Kingswood, Melbourne, Perth
Age
18 years and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Brisbane, Camperdown, Darlinghurst, East Melbourne, Fitzroy, Melbourne, Nedlands, Westmead
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Melbourne
Age
18 years and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Where
Adelaide, Coffs Harbour, Fitzroy, Melbourne, Port Macquarie, South Brisbane, Westmead, West Perth
Age
18 years to 64 years
People
602 worldwide
Run by
AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Blacktown, Heidelberg, Melbourne, Richmond, Saint Leonards, Wollongong
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
Phase 1/2Taking people
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Where
Camperdown, East Melbourne
Age
18 years and over
People
101 worldwide
Run by
AstraZeneca
See details and how to joinNCT07681596
Phase 1/2Taking people
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Where
Melbourne, Richmond, Wollongong
Age
18 years and over
People
258 worldwide
Run by
Sanofi
See details and how to joinNCT04643002
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Adelaide, Douglas, Greenslopes, Kogarah, Melbourne, Murdoch, St Albans
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00